Board to approve September 2026 quarterly and half-year results

Results View source PDF Explain this filing

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹337.20

prior close

₹350.85

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%+3.0% vs market

Pharmaceuticals peers, median of 173sector+2.0%+2.7% vs sector

On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

-0.1

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+1.7+3.0+2.0+2.7

Next day

+5.7pendingpending+2.6+3.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board will meet on 4 November 2026 to approve unaudited standalone and consolidated results for the quarter and six months ended 30 September 2026, along with the auditor's limited review. The trading window remains closed until 48 hours after results are published.

Likely market impact

No figures or auditor change are disclosed. Results are scheduled after the 4 November board meeting, with trading closed until 48 hours after publication.